[1] |
American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: ma-nagement guidelines of the American Thyroid Association[J]. Thyroid, 2009, 19(6):565-612.
|
[2] |
Castinetti F, Moley J, Mulligan L, et al. A comprehensive review on MEN2B[J]. Endocr Relat Cancer, 2018, 25(2):T29-T39.
|
[3] |
Yip L, Cote GJ, Shapiro SE, et al. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship[J]. Arch Surg, 2003, 138(4):409-416.
|
[4] |
Maciel RMB, Camacho CP, Assumpcao LVM, et al. Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study[J]. Endocr Connect, 2019, 8(3):289-298.
|
[5] |
Voss RK, Feng L, Lee JE, et al. Medullary thyroid carcinoma in MEN2A: ATA moderate- or high-risk RET mutations do not predict disease aggressiveness[J]. J Clin Endocrinol Metab, 2017, 102(8):2807-2813.
|
[6] |
Valiveru RC, Agarwal G, Agrawal V, et al. Hereditary medullary thyroid carcinoma: genotype, phenotype and outcomes in a north Indian cohort[J]. World J Surg, 2021, 45(6):1785-1793.
|
[7] |
Wells SA Jr, Asa SL, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610.
|
[8] |
Amodru V, Taieb D, Guerin C, et al. MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives[J]. Endocrine, 2020, 69(3):496-503.
|
[9] |
王宇, 田文, 嵇庆海, 等. 甲状腺髓样癌诊断与治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(9):1012-1020.
|
[10] |
Mathiesen JS, Kroustrup JP, Vestergaard P, et al. Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study[J]. Clin Epide-miol, 2018, 10:1479-1487.
|
[11] |
Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis[J]. J Med Genet, 2000, 37(11):817-827.
|
[12] |
Martins-Costa MC, Cunha LL, Lindsey SC, et al. M918V RET mutation causes familial medullary thyroid carcinoma: study of 8 affected kindreds[J]. Endocr Relat Cancer, 2016, 23(12):909-920.
|
[13] |
van Den Broek MFM, van Santen HM, Valk GD, et al. Children with multiple endocrine neoplasia type 2B: not tall and marfanoid, but short with normal body proportions[J]. Clin Endocrinol(Oxf), 2021, 95(3):453-459.
|
[14] |
Jung KY, Kim SM, Kim MJ, et al. Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea[J]. Surgery, 2018, 164(2):312-318.
|
[15] |
Frank-Raue K, Buhr H, Dralle H, et al. Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype[J]. Eur J Endocrinol, 2006, 155(2):229-236.
|
[16] |
Raue F, Bruckner T, Frank-Raue K. Similar stage-dependent survival and outcome in sporadic and hereditary medullary thyroid carcinoma[J]. J Clin Endocrinol Metab, 2021, 106(9):e3582-e3591.
|
[17] |
赵坚强, 刘乃芳, 梁忠, 等. 整合术前RET原癌基因和血清降钙素检测的MEN2的预防性甲状腺切除[C]. 第六届全国甲状腺肿瘤学术大会论文集, 2014:415-415.
|
[18] |
Zhang G, Jiang Y, Zhang S, et al. Genetic analysis of a hereditary medullary thyroid carcinoma case with normal preoperative serum calcitonin levels[J]. Pathol Res Pract, 2019, 215(10):152529.
|
[19] |
Maxwell P. Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker[J]. Br J Biomed Sci, 1999, 56(3):209-214.
|
[20] |
Passos I, Stefanidou E, Meditskou-Eythymiadou S, et al. A review of the significance in measuring preoperative and postoperative carcinoembryonic antigen (CEA) values in patients with medullary thyroid carcinoma(MTC)[J]. Medicina (Kaunas), 2021, 57(6):609.
|
[21] |
张刚, 陈懿, 徐琰. CEA异常升高首诊的遗传性甲状腺髓样癌家系的临床诊治和基因突变分析[J]. 中国医药导报, 2018, 15(14):83-85.
|
[22] |
Chen H, Sippel RS, O′dorisio MS, et al. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer[J]. Pancreas, 2010, 39(6):775-783.
|
[23] |
Agarwal G, Sadacharan D, Aggarwal V, et al. Surgical management of organ-contained unilateral pheochromocytoma: comparative outcomes of laparoscopic and conventional open surgical procedures in a large single-institution series[J]. Langenbecks Arch Surg, 2012, 397(7):1109-1116.
|
[24] |
Park H, Kim HI, Choe JH, et al. Surgeon volume and long-term oncologic outcomes in patients with medullary thyroid carcinoma[J]. Ann Surg Oncol, 2021, 28(13):8863-8871.
|
[25] |
Mishra A, Mishra SK, Agarwal A, et al. Metastatic diffe-rentiated thyroid carcinoma: clinicopathological profile and outcome in an iodine deficient area[J]. World J Surg, 2002, 26(2):153-157.
|
[26] |
Zhang X, Yan D, Wang J, et al. Is new American Thyroid Association risk classification for hereditary medullary thyroid carcinoma applicable to Chinese patients? a single-center study[J]. Chin J Cancer Res, 2017, 29(3):223-230.
|
[27] |
Raue F, Bruckner T, Frank-Raue K. Long-term outcomes and aggressiveness of hereditary medullary thyroid carcinoma: 40 years of experience at one center[J]. J Clin Endocrinol Metab, 2019, 104(10):4264-4272.
|